Research Topics
| M AroraSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysisMukta Arora
Department of Hematology, Oncology and Transplant, University of Minnesota, 420 Delaware St SE, Minneapolis MN 55455, USA
Blood 117:6714-20. 2011..Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability...- Therapy of chronic graft-versus-host diseaseMukta Arora
Division of Hematology, Oncology and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis MN 55455, USA
Best Pract Res Clin Haematol 21:271-9. 2008..A multidisciplinary approach to evaluating and managing patients with cGVHD is preferred, and disciplined, prospective study of new therapies is essential to make further progress in its understanding and treatment... - Polymorphisms in the base excision repair pathway and graft-versus-host diseaseM Arora
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Leukemia 24:1470-5. 2010..81, 95% CI: 1.29-2.54, P=0.001). These results show that SNPs in the BER pathway can be used as genetic biomarkers to predict those at high risk for GVHD toward whom novel prophylactic strategies could be targeted... - HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemiaMukta Arora
University of Minnesota, National Marrow Donor Program, Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA
J Clin Oncol 27:1644-52. 2009..However, the utility and outcome associated with transplants from URDs compared with those from MSDs remains undefined... 
New classification of chronic GVHD: added clarity from the consensus diagnosesM Arora
Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 43:149-53. 2009..1% (95% CI 68-94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients...
Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myelomaM Arora
Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
Bone Marrow Transplant 35:1133-40. 2005..Allogeneic HCT may be suitable in younger patients, soon after diagnosis, and in those with chemosensitive disease...- Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)Mukta Arora
Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 13:1145-52. 2007..In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM... - Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host diseaseM Arora
Department of Medicine, University of Minnesota, Minneapolis 55455, USA
Biol Blood Marrow Transplant 7:265-73. 2001..The value of thalidomide as salvage therapy requires further study... - Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trialM Markova
Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
Bone Marrow Transplant 39:193-9. 2007..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens... - Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcomeMichael B Tomblyn
Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
J Clin Oncol 27:3634-41. 2009..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care... - A modified comorbidity index for hematopoietic cell transplantationT E DeFor
Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 45:933-8. 2010..In conclusion, we are introducing the MCI which may have higher discriminating and predictive power for overall survival and NRM. Validation of the HCT-CI and the MCI in larger and separate cohorts of HCT recipients is still needed... - Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA matchJason Dehn
National Marrow Donor Program, Minneapolis, Minnesota 55413 1753, USA
Biol Blood Marrow Transplant 14:1334-40. 2008.... - Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemiaTheresa Hahn
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Clin Oncol 26:5728-34. 2008..No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved... - Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysisCatherine M Flynn
Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Am J Hematol 82:867-72. 2007..Advances in GVHD management and new approaches for relapsed or refractory disease are necessary to improve these outcomes... - Why are urban Indian 6th graders using more tobacco than 8th graders? Findings from Project MYTRIM H Stigler
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
Tob Control 15:i54-60. 2006..To investigate why urban Indian 6th graders may be using more tobacco than urban Indian 8th graders... - Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donorNavneet S Majhail
Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:282-9. 2008..A careful review of existing comorbidities is necessary when considering older patients for HCT... - Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapseDaniel J Weisdorf
University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 15:1475-8. 2009..In this analysis, greater histoincompatibility can augment GVHD, but does not improve protection against relapse; thus the best donor remains the most closely matched donor... - Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplantsNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:985-92. 2008..The HCT-CI, although a useful tool for capturing pretransplant comorbidity and risk-assessment, needs to be further validated prior to adopting it for routine clinical use... - Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphomaNoel Laudi
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, USA
Am J Hematol 81:519-24. 2006..No autologous transplant-related deaths occurred. Allogeneic transplant-related mortality was 29% (95% CI 6-52%) at 1 and 5 years. HSCT for MCL can yield extended disease control and long-term survival... - Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantationsBharat Thyagarajan
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 16:1084-9. 2010..These findings suggest that SNPs in the BER pathway can be used as genetic biomarkers to predict individuals at high risk for TRM and disease relapse. Modulation of pretransplant conditioning may alter risk in these patients... - Chronic graft-versus-host disease: a prospective cohort studyMukta Arora
Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 9:38-45. 2003..Recognition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to be identified to improve survival and limit toxicity of prolonged immunosuppression... - Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor StudyChristopher J Fraser
Pediatric Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Blood 108:2867-73. 2006..We conclude that active cGVHD has a significant impact on many aspects of the overall health status of HCT survivors and that, most importantly, those successfully treated for cGVHD do not appear to have long-term impairments... - Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplantsB Thyagarajan
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
Int J Immunogenet 40:108-15. 2013..02). None of the SNPs were associated with acute or chronic GvHD risk. These findings suggest that genetic variants in the vascular adhesion molecules may be used to identify patients at high risk for TRM... - High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantationN S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
Bone Marrow Transplant 43:49-54. 2009..We conclude that metabolic syndrome occurs frequently among allogeneic HCT survivors who are seen by transplant physicians. Approaches to screening, prevention and management of metabolic syndrome should be developed for HCT recipients... - Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphomaNavneet S Majhail
Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 12:1065-72. 2006..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL... - Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphomaNoel Laudi
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 11:129-35. 2005.... - Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myelomaMukta Arora
Department of Medicine, University of Minnesota, Minneapolis 55455, USA
Biol Blood Marrow Transplant 10:395-404. 2004..Two cycles of priming chemotherapy plus autologous transplantation yields survival rates similar to those in published reports, including those using tandem transplantation... - Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter studyGorgun Akpek
Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
Blood 102:802-9. 2003..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed... - Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 112:3500-7. 2008..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT... - Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt
M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
Br J Haematol 137:461-7. 2007..Most patients now receive a trial of imatinib before proceeding to HCT...